Using Healthcare Financing and Digital Technology to Improve Hypertension Prevention and Control in Tanzania

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-70
SponsorDr. Karen Yeates

About this trial

The aim of our proposed program is to develop and implement a multilevel, multicomponent and health-financing intervention that will facilitate the scale up of evidence-based strategies to improve non-communicable diseases prevention, detection and control in Tanzania. The investigators will accomplish this by: 1) adapting two intervention components that are candidates for inclusion in a highly effective optimized strategy (called STOP-NCDs) and; (b) Assess their individual and combined effectiveness and 2) conducting a robust, mixed-methods evaluation of the implementation process and assess factors that may influence implementation and sustainability for delivering and scaling the optimized STOP-NCDs strategy. The investigators will select and/or adapt intervention components making up the optimized STOP-NCDs strategy. Using a hybrid clinical-effectiveness implementation design, the investigators will conduct a study in 2 sequential phases: 1) A clinical-effectiveness phase in which the investigators evaluate the effect of our combined strategies (task-sharing and WelTel) versus Usual Care, on rates of systolic BP reduction at 12 months; as well as other secondary outcomes including diagnosis and treatment of diabetes and, patient knowledge of CVD risks and prevention, and, other features of health provider NCD prevention activities. 2) A post-implementation phase in which the investigators use the RE-AIM framework to evaluate changes in the adoption and maintenance of our combined strategies in participating iCHF health facilities across Kilimanjaro region. The investigators will use the WelTel communication and Patient Management platform for to deliver culturally and contextually appropriate evidence-based text messaging to patients. It allows for quality improvement and is a unique tool for our program to scaling low-cost interventions that provide capabilities for tracking of health system service uptake, quality-metrics at health facilities, drug stock-out management, and patient-centered behavioral health interventions. Deployment of WelTel will allow for integration of NCD prevention targeted health services to all adult iCHF members across differing life stages and NCD risk and have a significant impact on increasing quality of care and sustainability of health financing and performance-based incentives through improved prescribing, patient engagement, medication adherence and healthy behaviour change.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All adults with uncontrolled HTN who receive care through iCHF membership and are able to provide informed consent.

Disqualifiers

Adults with controlled HTN or those without a diagnosis of HTN

Unable or unwilling to provide informed consent

Trial design

Design model

Factorial

Treatments tested in this trial

  • Nurse-delivered care using WelTel check-ins and BCC SMS

    Other intervention

    Nurse-delivered HTN, DM and CVD risk assessment, diagnosis and Management (through NIMONCD) using WelTel check-ins and BCC SMS

  • Community-based peer-support model

    Other intervention

    Community-based peer- support model using Weltel check-ins and BCC SMS and facilitated group self monitoring

Treatment groups

1,320 Participants
are divided into 4 treatment groups
Group A: Enhanced Usual Care (EUC)No intervention 0 interventions
Group B: EUC + community supportActive comparator 1 intervention
Group C: EUC + nurse-delivered check insActive comparator 1 intervention
Group D: EUC + community support + nurse-delivered check insActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

Systolic blood pressure

Change in systolic blood pressure from baseline to last follow-up visit

Time frame
12 months

Secondary outcomes

1

Blood pressure control

Proportion of participants with controlled blood pressure (\<140 mm Hg for systolic and \<90 mm Hg for diastolic) at the last follow-up visit

Time frame
12 months

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Dr. Karen Yeates

Lead sponsor

Queen's University

Sponsor institution

Kilimanjaro Clinical Research Institute

Collaborator

Muhimbili University of Health and Allied Sciences

Collaborator

This trial is not recruiting at the moment. You can still explore other options: